Physician profile
James Holleran
NPI 1568425049
$11,183.54
in general payments reported to CMS, 2019-2025
72 companies · $1,713 in 2025
The $1,713 reported for 2025 was more than what 92% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,427 · 2020: $1,362 · 2021: $1,800 · 2022: $1,356 · 2023: $1,828 · 2024: $1,697 · 2025: $1,713.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,238.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,238.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,606.53 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $1,179.82 | 2019-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $838.70 | 2019-2025 | Jardiance, Ofev |
| Abbvie INC. | $814.18 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $793.17 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Pfizer INC. | $676.59 | 2019-2025 | |
| Amgen INC. | $591.79 | 2019-2025 | Tezspire, Otezla, Repatha |
| Lilly USA, LLC | $416.61 | 2019-2025 | Mounjaro, Zepbound, Trulicity |
| Merck Sharp & Dohme LLC | $391.87 | 2019-2025 | Zerbaxa, Gardasil 9, Capvaxive |
| Regeneron Healthcare Solutions, INC. | $338.96 | 2022-2025 | Dupixent |
| Baxter Healthcare | $300.58 | 2022-2024 | Hillrom - Vest System Model 105 Home Care, Hillrom - Life 2000 Ventilation System |
| Novartis Pharmaceuticals Corporation | $200.05 | 2019-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $185.27 | 2019-2024 | Glassia |
| Janssen Pharmaceuticals, INC | $161.83 | 2021-2024 | Xarelto |
| Actelion Pharmaceuticals US, INC. | $149.46 | 2021-2024 | Opsumit, Uptravi |
Show all 72 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Holleran listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.